Industry Insights
Latest in gene therapy and rare disease
FierceBiotech
J&J axes eye disease gene therapy after key phase 2b readout
Johnson Johnson has stopped development of an eye disease gene therapy after reviewing data from one of its key readouts for 2026.
GEN News
AI Could Give CGT Sector Deeper Manufacturing Insights and Greater Control
AI can help cell and gene therapy firms gain deeper insights about their complex production processes. The ultimate benefit of the technology will be helping industry move from reactive to predictive